1 Genetic Profile and Onset Features of 1005 Patients with

2 Charcot-Marie-Tooth disease in Japan

- 3
- 4 Akiko Yoshimura, MM¹, Jun-Hui Yuan, MD, PhD¹, Akihiro Hashiguchi, MD, PhD¹,
- 5 Masahiro Ando, MD¹, Yujiro Higuchi, MD, PhD¹, Tomonori Nakamura, MD, PhD¹,
- 6 Yuji Okamoto, MD, PhD¹, Masanori Nakagawa, MD, PhD², Hiroshi Takashima, MD,
- 7 PhD^{1*}
- 8
- 9 1 Department of Neurology and Geriatrics, Kagoshima University
- 10 Graduate School of Medical and Dental Sciences, Kagoshima, Japan
- 11 2 North Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan

12

- 13 *Corresponding author: Dr. Hiroshi Takashima
- 14 Professor and Chairman
- 15 Department of Neurology and Geriatrics, Kagoshima University
- 16 Graduate School of Medical and Dental Sciences
- 17 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima 890-8520, Japan
- 18 TEL: +81-99-275-5330 FAX: +81-99-265-7164
- 19 E-mail: thiroshi@m3.kufm.kagoshima-u.ac.jp
- 20
- 21 Word count: 2848 words
- 22 **References:** 27
- 23 Keywords Charcot-Marie-Tooth disease; Molecular epidemiology; next generation
- 24 sequencing; Gene panel

1 ABSTRACT

2	Objective To identify the genetic characteristics in a large-scale of patients with
3	Charcot-Marie-Tooth disease (CMT) patients.
4	Methods From May 2012 to August 2016, we collected 1005 cases with suspected
5	CMT throughout Japan, whereas PMP22 duplication/deletion were excluded in advance
6	for demyelinating CMT cases. We performed next generation sequencing targeting
7	CMT-related gene panels using Illumina MiSeq or Ion Proton, then analyzed the
8	gene-specific onset age of the identified cases and geographical differences in terms of
9	their genetic spectrum.
10	Results From 40 genes, we identified pathogenic or likely pathogenic variants in 301
10 11	Results From 40 genes, we identified pathogenic or likely pathogenic variants in 301 cases (30.0%). The most common causative genes were <i>GJB1</i> ($n = 66, 21.9\%$), <i>MFN2</i>
11	cases (30.0%). The most common causative genes were <i>GJB1</i> (n = 66, 21.9%), <i>MFN2</i>
11 12	cases (30.0%). The most common causative genes were $GJB1$ (n = 66, 21.9%), $MFN2$ (n = 66, 21.9%), and MPZ (n = 51, 16.9%). In demyelinating CMT, variants were
11 12 13	cases (30.0%). The most common causative genes were <i>GJB1</i> (n = 66, 21.9%), <i>MFN2</i> (n = 66, 21.9%), and <i>MPZ</i> (n = 51, 16.9%). In demyelinating CMT, variants were detected in 45.7% cases, and the most common reasons were <i>GJB1</i> (40.3%), <i>MPZ</i>
11 12 13 14	cases (30.0%). The most common causative genes were <i>GJB1</i> (n = 66, 21.9%), <i>MFN2</i> (n = 66, 21.9%), and <i>MPZ</i> (n = 51, 16.9%). In demyelinating CMT, variants were detected in 45.7% cases, and the most common reasons were <i>GJB1</i> (40.3%), <i>MPZ</i> (27.1%), <i>PMP22</i> point mutations (6.2%), and <i>NEFL</i> (4.7%). Axonal CMT yielded a

early-onset CMT cases were most likely to receive a molecular diagnosis. Geographical
 distribution analysis indicated distinctive genetic spectrums in different regions of
 Japan.

4 Conclusions Our results updated the genetic profile within a large-scale of Japanese
5 CMT cases. Subsequent analyses regarding onset age and geographical distribution
6 advanced our understanding of CMT, which would be beneficial for clinicians.

 $\mathbf{7}$

8 INTRODUCTION

9	Charcot-Marie-Tooth disease (CMT) is the most common phenotype of inherited
10	peripheral neuropathy (IPN), the latter of which also encompass hereditary sensory and
11	autonomic neuropathy, hereditary neuropathy with liability to pressure palsy and
12	hereditary motor neuropathy (HMN). ¹ In terms of median motor nerve conduction
13	velocity (MNCV), CMT can be further classified into demyelinating CMT (MNCV $<$
14	38 m/s) and axonal CMT (MNCV \geq 38 m/s).
15	CMT is typically characterized by progressive motor and sensory
16	polyneuropathy, but it may also present with significant clinical heterogeneity. CMT

1	disease-causing genes, such as GARS (CMT2D and distal HMN5A), HSPB1 (CMT2F
2	and distal HMN2B), or IGHMBP2 (CMT2S and spinal muscular atrophy with
3	respiratory distress type 1), often produce other IPN phenotypes. ^{2 3 4} To date,
4	approximately 100 different genes have been linked to CMT-like phenotypes
5	(https://neuromuscular.wustl.edu/). Owing to its clinical complexity and genetic
6	diversity, the clinical subtyping of CMT is always laborious and difficult.
7	The development of next-generation sequencing (NGS) technology allows us
8	to conduct gene panel sequencing simultaneously the targeting of numerous genes.
9	Within approximately 4 years, using two NGS systems successively, we have
10	completed genetic assessment in more than 1,000 Japanese cases with suspected CMT,
11	which enables us to describe the genetic and clinical features of these cases.
12	
13	MATERIALS AND METHODS
14	From May 2012 to August 2016, we collected blood or DNA samples from 1005

15 apparently unrelated patients throughout Japan with suspected CMT. These cases were

16 examined by their local neurologists or pediatricians, and were referred to our genetic

17 laboratory for diagnostic genetic test. Duplication/deletion mutation of *PMP22* was

 $\mathbf{2}$

3 On the basis of their family history, the included cases were grouped into

4 sporadic (n = 570, 56.7%), autosomal dominant (AD) or X-linked (n = 341, 33.9%),

5 autosomal recessive (AR; n = 72, 7.2%), or with an unknown inheritance pattern (no

6 clinical data, n = 22). All cases were further categorized as demyelinating CMT (n =

- 7 282), axonal CMT (n = 682) or unclassified type with no MNCV data or MNCV = 0 (n
- 8 = 41) referring to their records of electrophysiological examination.
- 9 Genomic DNA was extracted from peripheral blood using a Gentra Puregene
 10 Blood kit (QIAGEN, Valencia, California, USA), according to the manufacturer's
 11 instructions. The protocol was reviewed and approved by the Institutional Review
 12 Board of Kagoshima University. All cases and their family members provided written
 13 informed consent to participate in this study.
- 14

15 Targeted Gene panel sequencing

16 Primers were designed to cover the coding regions and exon/intron junctions of genes in

17 our CMT panel. Beginning in May 2012, we conducted mutation screening targeting 60

1	genes (Supplementary table 1) with the Illumina MiSeq platform (Illumina, San Diego,
2	California, USA). We used the same methodology as the one employed in a previous
3	study. ⁵ We completed genetic analysis in 437 cases with this system, concluding in
4	July 2014.
5	In September 2014, a custom Ion AmpliSeq gene panel targeting 72 IPNs
6	disease-causing or candidate genes (Supplementary table 1) was designed and
7	introduced. This panel consisted of 1,800 amplicons divided into 2 primer pools.
8	Library and template preparation was performed according to the manufacturer's
9	instructions, and then run on the Ion Proton (Thermo Fisher Scientific, Waltham,
10	Massachusetts, USA) applying the Ion PI Chip kit v2/v3 BC (Thermo Fisher Scientific,
11	Carlsbad, California, USA). We used the same methodology as the one employed in a
12	previous study. ⁶ Using this platform, we executed genetic assessment in 568 cases until
13	August 2016.

Data analysis and variant interpretation

1	We confirmed all previously reported pathogenic mutations with reference to the
2	Human Gene Mutation Database Professional 2017.3 (https://portal.biobase-
3	international.com/hgmd/pro). Moreover, we checked all variants against global
4	databases, including the 1000 Genomes (http://www.internationalgenome.org), the
5	Exome Sequencing Project (http://evs.gs.washington.edu/EVS) and the Exome
6	Aggregation Consortium (http://exac.broadinstitute.org/), as well as against Japanese
7	databases, including the integrative Japanese Genome Variation Database
8	(https://ijgvd.megabank.tohoku.ac.jp) and the Human Genetic Variation Database
9	(http://www.hgvd.genome.med.kyoto-u.ac.jp). We also checked the variants against our
10	in-house whole-exome sequencing database of individuals with non-IPNs. In silico
11	analyses of variants were performed using SIFT (http://sift.jcvi.org), PolyPhen2
12	(http://genetics.bwh.harvard.edu/pph2), PROVEAN (http://provean.jcvi.org/index.php),
13	Mutation Assessor (http://mutationassessor.org) and Condel (http://bg.upf.edu/fannsdb).
14	We completed the annotation process using the CLC Genomic Workbench software and
15	an in-house R script. All suspected variants were validated using Sanger sequencing and
16	interpreted according to the American College of Medical Genetics and Genomics
17	standards and guidelines. ⁷

RESULTS

3 Genetic Profile

4	Among the 1005 cases with suspected CMT, we detected pathogenic or likely
5	pathogenic variants in 301 cases (30.0%). The most common genetic causes in the
6	mutation-positive cases were GJB1 and MFN2, and each accounted for 21.9% (66
7	cases). Within MFN2, 40 types of reported and 3 novel variants (two pathogenic and 1
8	likely pathogenic) were identified. The following genetic causes were MPZ (n = 51,
9	16.9%), <i>HSPB1</i> (n = 14, 4.6%), <i>PMP22</i> point mutations (n = 13, 4.3%), <i>GDAP1</i> (n = 9,
10	3.0%), <i>NEFL</i> (n = 9, 3.0%), <i>MME</i> (n = 8, 2.7%), <i>BSCL2</i> (n = 6, 2.0%), <i>MARS</i> (n = 6,
11	2.0%), <i>DNM2</i> (n = 5, 1.7%), <i>SETX</i> (n = 5, 1.7%), <i>SH3TC2</i> (n = 5, 1.7%), <i>PRX</i> (n = 4),
12	<i>GARS</i> (n = 3), <i>IGHMBP2</i> (n = 3), <i>LRSAM1</i> (n = 3), <i>AARS</i> (n = 2), <i>ARHGEF10</i> (n = 2),
13	<i>FGD4</i> (n = 2), <i>SACS</i> (n = 2), <i>SBF2</i> (n = 2), <i>TRPV4</i> (n = 2), and <i>TTR</i> (n = 2). Pathogenic
14	or likely pathogenic variants were also detected in COA7, DCTN1, DHTKD1, EGR2,
15	FBLN5, GALC, GAN, HARS, HSPB3, HSPB8, INF2, KARS, MTMR2, PRPS1, RAB7A
16	and SOX10 in single cases. (Figure 1) Additionally, digenic variants were identified in

1	five cases, which were variants in SETX (likely pathogenic) and ARHGEF10 (likely
2	pathogenic); SH3TC2 (biallelic, likely pathogenic) and SACS (biallelic, likely
3	pathogenic); LRSAM1 (likely pathogenic) and MARS (likely pathogenic); HARS (likely
4	pathogenic) and ARHGEF10 (likely pathogenic); and MFN2 (reported, pathogenic) and
5	PMP22 (reported pathogenic).
6	In terms of sporadic cases, detection rate was 21.9% (125/570), comprising
7	108 monoallelic and 18 biallelic variants. Molecular diagnosis was accomplished in
8	44.6% (152/341) cases with AD or X-linked inheritance and in only 25.0% (18/72) of
9	cases with AR. In demyelinating CMT cases, 45.7% (129/282) received a genetic
10	diagnosis, and mutations in GJB1 (40.3%) and MPZ (27.1%) were the most common
11	reasons, accounting for 67.4% of all mutation-positive cases. Among cases with axonal
12	CMT, mutation detection rate was 22.9% (156/682), with MFN2 as the most frequent
13	causative gene, accounting for 37.2% of all mutation-positive cases, followed by MPZ
14	(9.0%), <i>HSPB1</i> (8.3%), and <i>GJB1</i> (7.7%), <i>GDAP1</i> (5.1%) and <i>MME</i> (5.1%). (Figure 2)
15	

Onset age analysis

1	We analyzed the onset age in the mutation-positive CMT cases and attempted to specify
2	their onset features. The CMT onset age of all the patients was determined to be when
3	either of their parents noticed any motor abnormalities in their children, or when the
4	patients themselves began to be aware of their motor or sensory dysfunctions. In cases
5	with demyelinating CMT, 104/282 (36.9%) cases developed clinical symptoms in the
6	first decade of life, and pathogenic or likely pathogenic variants were identified in 57 of
7	these cases (54.8%). In the same age group, 58 out of 190 cases (30.5%) with axonal
8	CMT received a molecular diagnosis, which also yielded the highest diagnostic rate.
9	Unexpectedly, cases with demyelinating CMT with onset in the seventh decade
10	demonstrated the highest diagnostic rate of 66.7% (6/9). (Figure 3A, 3B)
11	The majority (48/58cases) of cases with MFN2 variants were manifested with
12	an early-onset (0~20 years) axonal polyneuropathy. Demyelinating neuropathy was
13	predominant in cases with GJB1 variants, with case numbers decreasing with age. A
14	two-peak pattern was observed in cases with MPZ variants, consisting of a peak of
15	demyelinating type with onset age in the first decade, and a second peak of axonal type
16	in cases with disease onset during the fifth and six decades. The most common onset

1	age of cases with <i>HSPB1</i> variants was during the six decade. Most cases with <i>PMP22</i>
2	point variants (7/13 cases) developed demyelinating neuropathy in the first decade, and
3	the majority of cases with NEFL variants presented with a demyelinating phenotype at a
4	younger age. (Figure 3C)
5	Regarding two genes linked to AR-CMT, GDAP1 and MME, we noted that
6	cases with biallelic variants of GDAP1 developed clinical manifestations earlier than
7	those with monoallelic variants; cases with biallelic variants in MME commonly
8	presented with late-onset axonal neuropathies. (Figure 3D)
9	
10	Geographic distribution analysis
11	We conducted a geographic distribution analysis on the basis of all available medical
12	records, but without further validation of their familial place of origin. Here, Japan was
13	separated into eight regions. Variants in GJB1, MFN2 and MPZ were identified to be
14	the top three causative genes in six regions of Japan. Therein, MFN2 was found as the
15	most common cause of CMT in northern (Hokkaido and Tohoku) and southern Japan
16	(Chugoku and Kyushu/Okinawa), while GJB1-related CMT was more prevalent in

1	middle Japan (particularly in Kanto and Kinki). In Hokkaido region (A), MFN2 variants
2	accounted for more than half of all mutation-positive cases, and no case with MPZ
3	variant was identified. In Shikoku (G), a characteristic high incidence of NEFL variants
4	was observed. (Figure 4)

 $\mathbf{5}$

DISCUSSION

Using two targeted gene panel sequencing systems, we genetically analyzed 1005 cases
with suspected CMT to demonstrate their genetic profile. To the best of our knowledge,
this is the largest Asian study to date. The total diagnostic rate of our study was 30.0%
(301 cases), and remarkable genetic heterogeneity was recognized that pathogenic or
likely pathogenic variants were detected from 40 genes. We diagnosed 27.7% cases
with the Illumina MiSeq targeting 60 genes, and 31.7% cases with the Ion Proton
targeting 72 genes. Cases with demyelinating CMT received a much higher diagnostic
rate (45.7% vs. 22.9%) and lower genetic diversity than axonal type.
To date, genetic spectrum studies of CMT have been completed in multiple
countries (Table 1). The PMP22 duplication/deletion mutations, accounting for 23.3%

1	of demyelinating CMT in Japan, ⁸ were not involved in this study and were removed
2	from the original data of previous studies to facilitate comparison. Consequently, we
3	found that three genes, GJB1, MFN2, and MPZ, were the leading reasons in the present
4	study, using data from Germany, ⁹ USA, ¹⁰ UK, ¹¹ Norway, ¹² and Denmark ¹³ studies;
5	however, these results differ from previous reports from Japan, ⁸ Spain, ¹⁴ Italy, ¹⁵
6	Korea ¹⁶ and a cross-country study. ¹⁷ Particularly, in the other Japanese study, ⁸
7	regarding other genes with mutation frequency higher than 1%, PMP22 (3.3%), NEFL
8	(2.7%) and <i>PRX</i> $(1.7%)$ have been reported, whereas we detected <i>HSPB1</i> $(1.4%)$ and
9	PMP22 (1.3%) in the present study. A sampling bias should be considered to have
10	contributed to these differences.
11	In cases with monoallelic variants, $GJB1$ (n = 66), $MFN2$ (n = 65), and MPZ
12	(n = 51) were the top three genes, accounting for 68.7% of all mutation-positive cases.
13	Clinically, the majority of cases with $MFN2$ variants (n = 58) showed axonal phenotype,
14	making MFN2 as the most common reason of axonal CMT. Twelve cases with GJB1
15	variants exhibited axonal phenotype, whereas the other 52 cases exhibited the

demyelinating phenotype. Cases with *MPZ* variants also exhibited both axonal (n = 14)
 and demyelinating (n = 35) phenotypes.

3	In cases with biallelic variants, <i>MME</i> accounted for 22.2% ($n = 8$) of all
4	mutation-positive cases, followed by <i>SH3TC2</i> ($n = 5, 13.9\%$). In 2016 we have reported
5	that MME gene, which encodes neprilysin, is responsible for a late-onset AR-CMT type
6	2T. ⁶ Shortly thereafter, monoallelic rare variants have been reported to be associated
7	with axonal polyneuropathies or dominant spinocerebellar ataxia with neuropathy. 18 19
8	In the present study, monoallelic variants were detected in family members of four
9	cases with AR-CMT2T, none of whom developed notable clinical manifestations. We
10	also identified digenic variants from five cases (approximately 0.5%), the majority of
11	which were likely pathogenic (8/10); further study is required to identify whether the
12	combinatorial effect of these variants contributes to the phenotypic variability as disease
13	burden.
14	The onset age distribution of our CMT cases suggested an evident clustering

- 15 at the first decade, regardless of axonal or demyelinating phenotype. Our targeted gene
- 16 panel sequencing yielded a significantly high diagnostic rate of axonal (30.5%) and

1	demyelinating (54.8%) CMT for individuals diagnosed within the first decade of life.
2	This result is not surprising given that genetic factors are more common than acquired
3	factors in cases with early-onset polyneuropathies. Early onset is also a typical feature
4	of cases with GJB1, MFN2, MPZ (demyelinating type), PMP22 (point variants), NEFL,
5	and GDAP1 (biallelic) variants. In contrast, MPZ (axonal type) and HSPB1 variants
6	always produce a late-onset phenotype. For patients with late-onset demyelinating CMT
7	with an onset age between the fifth and sixth decade, a significant decline of diagnostic
8	rate was observed, which might be due to noninherited factors or to undiscovered
9	genetic causes. Interestingly, however, demyelinating CMT cases with onset at the
10	seventh decade, yielded the highest diagnostic rate (6/9), which could be a coincidence
11	owing to the mutations detected in various genes. Taken together, because the number
12	of case of demyelinating CMT with onset age older than 40 years was limited, more
13	samples should be collected for validating these unexpected results in the future.
14	We performed a geographic distribution analysis to elucidate the effect of
15	geography on the genetic spectrum of our cases. GJB1, MFN2, and MPZ were the top
16	three causative genes associated with CMT throughout the most regions in Japan.

1	Although our case numbers were limited, we observed an unexpectedly high frequency
2	of NEFL variants in Shikoku region, which was indicated in a previous study reporting
3	that <i>NEFL</i> variants accounted for a much higher proportion of CMT cases (2.7%) 8
4	Unfortunately, geographic distribution data were not available in the previous report.
5	This unusually high frequency of NEFL variants was unlikely to be caused by a founder
6	effect, because all these variants were completely different. High frequency of MFN2
7	variants and the absence of the MPZ variant were identified in Hokkaido. Our findings
8	suggest that geographic regions could give rise to the variable genetic spectrum and
9	diagnostic rate of CMT, and future well-powered analyses will be helpful to clarify
10	these findings.
11	Within our CMT-related gene panels, the role of several genes still require
12	further validation. Therein, six variants were detected in MARS, consisting of a
13	previously reported P800T mutation (4 cases) and two novel likely pathogenic variants.
14	In two of the four pedigrees with P800T, cosegregation of genotype and phenotype was
15	identified. For the two novel variants, further study is required to validate their
16	pathogenicity. Besides, we also found two heterozygous variants, G585S and W426G in

1	GALC gene (NM_000153.3) from one patient. GALC was known as the responsible
2	gene for Krabbe disease; however, peripheral neuropathy was the original and
3	predominant symptom of our patient, which is comparable with a former Japanese
4	patient with isolated peripheral neuropathy. 20
5	Recently, a number of new causative genes, such as those encoding MORC
6	family CW-type zinc finger 2 (MORC2), minichromosome maintenance complex
7	component 3 associated protein, neurofilament protein heavy polypeptide,
8	diacylglycerol O-acyltransferase 2, dystrophin-related protein 2, cytochrome c oxidase
9	subunit VIa polypeptide 1 and peripheral myelin protein 2 (PMP2) were associated with
10	CMT phenotypes. ^{21 22 23 24 25 26} These genes were not involved in any of our gene
11	panels, but a high frequency (2.7%) of MORC2 variants in axonal CMT was revealed
12	by whole-exome sequencing in our laboratory. ²⁷ These genes should be included in the
13	upcoming version of our gene panel, and the diagnostic rate would be increased.
14	In conclusion, using targeted gene panel sequencing, we demonstrated the
15	genetic features and geographical differences in a nationwide group of cases with CMT
16	in Japan. Together with results of onset age analysis, our findings advanced the

1	understanding of this intractable disease. Our sequencing strategy was proved effective,
2	exempting for complicated and undefined subtyping in clinic. A limitation of this study
3	is that our library could not yield either the non-coding region or the structural variant
4	of these genes.
5	

7 Acknowledgements

8	The authors thank all patients and their families for participating in this study and
9	appreciate the collaboration of their physicians. Additionally, the authors thank Mrs.
10	Aya Ebina and Tomoko Onishi for their excellent technical assistance. The authors also
11	thank Enago (www.enago.jp) for the English language review. We thank the Joint
12	Research Laboratory, at the Kagoshima University Graduate School of Medical and
13	Dental Sciences, for the use of their facilities.

1	Study funding This study is supported by grants from the research on the Nervous and
2	Mental Disorders and Research Committee for Charcot-Marie-Tooth Disease,
3	Neuropathy, and Applying Health and Technology of Ministry of Health, Welfare and
4	Labour, Japan (201331010B, 201610002B). This research is also supported by the
5	Research program for conquering intractable disease from Japan Agency for Medical
6	Research and development (AMED) (201442014A, 201442071A, 17929553), and
7	Japan Society for the Promotion of Science (26461275, 18H02742).
8	
9	Contributors AY, JHY, and MA contributed to laboratory data acquisition, analysis or
10	interpretation of data. AY, JHY, and HT contributed to drafting or revising of the
11	manuscript. AH, YH, and YO contributed to clinical data analysis or interpretation. TN
12	contributed to nerve conduction study analysis. MN and HT contributed to study
13	conception and supervision.
14	
15	Competing interests None declared.

References

2	1. Saporta MA, Shy ME. Inherited peripheral neuropathies. Neurol Clin
3	2013;31:597-619.
4	2. Antonellis A, Ellsworth RE, Sambuughin N, et al. Glycyl tRNA synthetase
5	mutations in Charcot-Marie-Tooth disease type 2D and distal spinal
6	muscular atrophy type V. American journal of human genetics
7	2003;72:1293-9.
8	3. Evgrafov OV, Mersiyanova I, Irobi J, et al. Mutant small heat-shock protein 27
9	causes axonal Charcot-Marie-Tooth disease and distal hereditary motor
10	neuropathy. Nature genetics 2004;36:602-6.
11	4. Grohmann K, Schuelke M, Diers A, et al. Mutations in the gene encoding
12	immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with
13	respiratory distress type 1. Nature genetics 2001;29:75-7.
14	5. Maeda K, Idehara R, Hashiguchi A, et al. A family with distal hereditary motor
15	neuropathy and a K141Q mutation of small heat shock protein HSPB1.
16	Intern Med 2014;53:1655-8.
17	6. Higuchi Y, Hashiguchi A, Yuan J, et al. Mutations in MME cause an
18	autosomal-recessive Charcot-Marie-Tooth disease type 2. Ann Neurol
19	2016;79:659-72.
20	7. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation
21	of sequence variants: a joint consensus recommendation of the American
22	College of Medical Genetics and Genomics and the Association for Molecular
23	Pathology. <i>Genet Med</i> 2015;17:405-24.
24	8. Abe A, Numakura C, Kijima K, et al. Molecular diagnosis and clinical onset of
25	Charcot-Marie-Tooth disease in Japan. J Hum Genet 2011;56:364-8.
26	9. Gess B, Schirmacher A, Boentert M, et al. Charcot-Marie-Tooth disease:
27	frequency of genetic subtypes in a German neuromuscular center population.
28	Neuromuscul Disord 2013;23:647-51.
29	10. DiVincenzo C, Elzinga CD, Medeiros AC, et al. The allelic spectrum of
30	Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathy.
31	Mol Genet Genomic Med 2014;2:522-9.

1	11. Murphy SM, Laura M, Fawcett K, et al. Charcot-Marie-Tooth disease: frequency
2	of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg
3	<i>Psychiatry</i> 2012;83:706-10.
4	12. Ostern R, Fagerheim T, Hjellnes H, et al. Diagnostic laboratory testing for
5	Charcot Marie Tooth disease (CMT): the spectrum of gene defects in
6	Norwegian patients with CMT and its implications for future genetic test
7	strategies. BMC Med Genet 2013;14:94.
8	13. Vaeth S, Christensen R, Duno M, et al. Genetic analysis of Charcot-Marie-Tooth
9	disease in Denmark and the implementation of a next generation sequencing
10	platform. <i>Eur J Med Genet</i> 2018
11	14. Sivera R, Sevilla T, Vilchez JJ, et al. Charcot-Marie-Tooth disease: genetic and
12	clinical spectrum in a Spanish clinical series. <i>Neurology</i> 2013;81:1617-25.
13	15. Manganelli F, Tozza S, Pisciotta C, et al. Charcot-Marie-Tooth disease:
14	frequency of genetic subtypes in a Southern Italy population. J Peripher
15	Nerv Syst 2014;19:292-8.
16	16. Nam SH, Hong YB, Hyun YS, et al. Identification of Genetic Causes of Inherited
17	Peripheral Neuropathies by Targeted Gene Panel Sequencing. Mol Cells
18	2016;39:382-8.
19	17. Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in
20	patients enrolled in the Inherited Neuropathies Consortium natural history
21	study: a cross-sectional analysis. J Neurol Neurosurg Psychiatry
22	2015;86:873-8.
23	18. Auer-Grumbach M, Toegel S, Schabhuttl M, et al. Rare Variants in MME,
24	Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset
25	Autosomal-Dominant Axonal Polyneuropathies. American journal of human
26	genetics 2016;99:607-23.
27	19. Depondt C, Donatello S, Rai M, et al. MME mutation in dominant
28	spinocerebellar ataxia with neuropathy (SCA43). <i>Neurol Genet</i> 2016;2:e94.
29	20. Adachi H, Ishihara K, Tachibana H, et al. Adult-onset Krabbe disease
30	presenting with an isolated form of peripheral neuropathy. Muscle Nerve
31	2016;54:152-7.
32	21. Sevilla T, Lupo V, Martinez-Rubio D, et al. Mutations in the MORC2 gene cause
33	axonal Charcot-Marie-Tooth disease. <i>Brain</i> 2016;139:62-72.

1	22. Ylikallio E, Woldegebriel R, Tumiati M, et al. MCM3AP in recessive
2	Charcot-Marie-Tooth neuropathy and mild intellectual disability. Brain
3	2017;140:2093-103.
4	23. Rebelo AP, Abrams AJ, Cottenie E, et al. Cryptic Amyloidogenic Elements in the
5	3' UTRs of Neurofilament Genes Trigger Axonal Neuropathy. American
6	journal of human genetics 2016;98:597-614.
7	24. Hong YB, Kang J, Kim JH, et al. DGAT2 Mutation in a Family with
8	Autosomal-Dominant Early-Onset Axonal Charcot-Marie-Tooth Disease.
9	<i>Hum Mutat</i> 2016;37:473-80.
10	25. Brennan KM, Bai Y, Pisciotta C, et al. Absence of Dystrophin Related Protein-2
11	disrupts Cajal bands in a patient with Charcot-Marie-Tooth disease.
12	Neuromuscul Disord 2015;25:786-93.
13	26. Tamiya G, Makino S, Hayashi M, et al. A mutation of COX6A1 causes a
14	recessive axonal or mixed form of Charcot-Marie-Tooth disease. American
15	journal of human genetics 2014;95:294-300.
16	27. Ando M, Okamoto Y, Yoshimura A, et al. Clinical and mutational spectrum of
17	Charcot-Marie-Tooth disease type 2Z caused by MORC2 variants in Japan.
18	<i>Eur J Neurol</i> 2017;24:1274-82.
19	
20	
21	
41	
22	
23	
24	
4 4	

1 Figure legends


2	Figure 1 Genetic spectrum of 301 cases with pathogenic or likely pathogenic variants.
3	The following genes are indicated: GJB1 (21.9%), MFN2 (21.9%), MPZ (16.9%),
4	HSPB1 (4.6%), PMP22 point mutation (4.3%), GDAP1 (3.0%), NEFL (3.0%), MME
5	(2.7%), BSCL2 (2.0%), MARS (2.0%), DNM2 (1.7%), SETX (1.7%), SH3TC2 (1.7%),
6	PRX (1.3%), GARS (1.0%), IGHMBP2 (1.0%), LRSAM1 (1.0%), AARS (0.7%),
7	ARHGEF10 (0.7%), FGD4 (0.7%), SACS (0.7%), SBF2 (0.7%), TRPV4 (0.7%), TTR
8	(0.7%), COA7 (0.3%), DCTN1 (0.3%), DHTKD1 (0.3%), EGR2 (0.3%), FBLN5 (0.3%),
9	GALC (0.3%), GAN (0.3%), HARS (0.3%), HSPB3 (0.3%), HSPB8 (0.3%), INF2
10	(0.3%), KARS (0.3%), MTMR2 (0.3%), PRPS1 (0.3%), RAB7A (0.3%), and SOX10
11	(0.3%).
12	Figure 2 Detection rate and proportional detection of variants in cases with
13	demyelinating and axonal CMT. * PMP22 point mutation.
14	Figure 3 Onset age analyses of mutation-positive cases. (A and B) Curve graph and
15	column diagram of varied onset age and diagnostic rate of axonal or demyelinating
16	CMT. (C) Diagram of disease onset features in cases with GJB1, MFN2, MPZ,

1	HSPB1, PMP22, and NEFL variants. (D) Diagram of disease onset features of cases
2	with monoallelic or biallelic variants of <i>GDAP1</i> and <i>MME</i> genes. A, axonal type; D,
3	demyelinating type; N, number; Y, year. * PMP22 point mutation.
4	Figure 4 Geographic analysis of genetic spectrum of CMT in Japan. Japan is divided
5	into eight regions (A–H), and axonal/demyelinating type and the causative genes are
6	indicated in different colors. Mutation-positive and total numbers of each region are
7	indicated around the pie chart. NE, not examined.

	GJB1	MFN2	MPZ	HSPB1	<i>PMP22</i> *	GDAP1	NEFL	MME	BSCL2	MARS	DNM2	SETX	SH3TC2	PRX	GARS	IGHMBP2	LRSAM1	Total
Our study	6.6%	6.6%	5.1%	1.4%	1.3%	0.9%	0.9%	0.8%	0.6%	0.6%	0.5%	0.5%	0.5%	0.4%	0.3%	0.3%	0.3%	30.0%
	(66)	(66)	(51)	(14)	(13)	(9)	(9)	(8)	(6)	(6)	(5)	(5)	(5)	(4)	(3)	(3)	(3)	(301/1005)
Japan, 2011 ⁸	8.3%	4.7%	1.7%	0	3.3%	0.3%	2.7%	/	/	/	0	/	/	1.7%	0.3%	/	/	29.9%
	(25)	(14)	(5)	(0)	(10)	(1)	(8)	/	/	/	(0)	/	/	(5)	(1)	/	/	(90/301)
UK, 2012 ¹¹	12.3%	5.0%	2.6%	0.3%	0.9%	1.0%	0.3%	/	0.2%	/	/	/	0.8%	/	/	/	/	24.9%
	(147)	(60)	(31)	(3)	(11)	(12)	(4)	/	(2)	/	/	/	(9)	/	/	/	/	(297/1192)
German, 2013 ⁹	13.1%	3.3%	5.8%	/	2.2%	0	0	/	/	/	/	/	0	0	0.6%	/	/	30.6%
	(47)	(12)	(21)	/	(8)	(0)	(0)	/	/	/	/	/	(0)	(0)	(2)	/	/	(110/360)
Norway, 2013 ¹²	4.0%	3.6%	3.3%	/	0	/	0.7%	/	/	/	/	/	/	/	/	/	/	11.6%
	(12)	(11)	(10)	/	(0)	/	(2)	/	/	/	/	/	/	/	/	/	/	(35/302)
Spain, 2013 ¹⁴	22.0%	1.6%	7.5%	2.8%	0.8%	16.5%	1.6%	/	/	/	/	/	11.0%	1.6%	0.4%	/	/	71.3%
1 ,	(56)	(4)	(19)	(7)	(2)	(42)	(4)	/	/	/	/	/	(28)	(4)	(1)	/	/	(181/254)
USA, 2014 ¹⁰	1.4%	0.9%	1.1%	0.1%	0.2%	0.1%	0.1%	/	/	/	/	/	0.2%	0.01%	0.1%	/	/	4.6%
	(215)	(138)	(170)	(10)	(30)	(22)	(22)	/	/	/	/	/	(26)	(1)	(13)	/	/	(679/14840


Italy, 2014 ¹⁵	14.4%	2.1%	7.2%	1.0%	7.2%	8.2%	1.0%	/	/	/	/	/	3.1%	/	/	/	/	49.5%
	(14)	(2)	(7)	(1)	(7)	(8)	(1)	/	/	/	/	/	(3)	/	/	/	/	(48/97)
CC, 2015 ¹⁷	11.2%	7.3%	7.0%	0.7%	1.8%	0.9%	1.2%	/	0.5%	/	/	/	1.5%	0.3%	0.2%	/	/	34.4%
	(107)	(70)	(67)	(7)	(17)	(9)	(11)	/	(5)	/	/	/	(14)	(3)	(2)	/	/	(328/954)
Korea, 2016 ¹⁶	14.8%	1.6%	3.3%	0	1.6%	0	0	/	0	1.6%	0	0	1.6%	0	0	0	0	26.2%
	(9)	(1)	(2)	(0)	(1)	(0)	(0)	/	(0)	(1)	(0)	(0)	(1)	(0)	(0)	(0)	(0)	(16/61)
Denmark, 2018 ¹³	2.7%	2.0%	2.3%	0	0.4%	0	0.1%	/	0	/	0.1%	0	0.1%	0	0.1%	/	0	8.3%
, _,	(32)	(24)	(27)	(0)	(5)	(0)	(1)	/	(0)	/	(1)	(0)	(1)	(0)	(1)	/	(0)	(98/1177)


Numbers in () indicate case numbers; /, no data. * PMP22 point mutation; CC, cross-country.




GAN, HARS, HSPB3, HSPB8, INF2, KARS, MTMR2, PRPS1, RAB7A, SOX10 (1 case each)

NE (not evoked)







Gene	AARS	APTX	ARHGEF10	DHH	DNM2	EGR2						
panel for	FGD4	FIG4	GAN	GARS	GDAP1	GJB1						
Miseq	HARS	HK1	HOXD10	HSPB1	HSPB8	KARS						
(60genes)	LITAF	LMNA	MARS	MED25	MFN2	MPZ						
	MTMR2	NDRG1	NEFL	PMP22	PRPS1	PRX						
	RAB7A	SBF2	SETX	SH3TC2	SLC12A6	SOX10						
	TDP1	TRPV4	TTR	YARS	20 candidate	genes						
Gene	AARS	APTX	ARHGEF10	BSCL2	DCAF8	DCTN1						
panel for	DHH	DHTKD1	DNM2	DYNC1H1	EGR2	FBLN5						
Ion	FBXO38	FGD4	FIG4	GALC	GAN	GARS						
Proton (72genes)	GDAP1	GJB1	GJB3	GNB4	HARS	HK1						
(7250103)	HOXD10	HSPB1	HSPB3	HSPB8	IGHMBP2	INF2						
	KARS	KIF1A	LITAF	LMNA	LRSAM1	MARS						
	MED25	MFN2	MME	MPZ	MTMR2	NDRG1						
	NEFL	PDK3	PLEKHG5	PMP22	PRPS1	PRX						
	RAB7A	REEP1	SACS	SBF1	SBF2	SETX						
	SH3TC2	SLC12A6	SLC5A7	SOX10	SURF1	TDP1						
	TFG	TRIM2	TRPV4	TTR	YARS	COA7						
	6 candidate genes											

Supplementary table 1 Gene panel list of Illumina MiSeq and Ion Proton